Detalhe da pesquisa
1.
Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
Am Heart J
; 198: 25-32, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653644
2.
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
Lancet
; 388(10060): 2607-2617, 2016 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27806902
3.
Three-Year Clinical Outcome of Patients with Coronary Disease and Increased Event Risk Treated with Newer-Generation Drug-Eluting Stents: From the Randomized DUTCH PEERS Trial.
Cardiology
; 137(4): 207-217, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28445871
4.
Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
Am Heart J
; 176: 28-35, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27264217
5.
Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II).
Am Heart J
; 175: 121-9, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27179731
6.
Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
Heart Vessels
; 31(11): 1731-1739, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26747438
7.
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
Lancet
; 383(9915): 413-23, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24183564
8.
Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.
Am Heart J
; 169(1): 69-77, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25497250
9.
Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial.
Catheter Cardiovasc Interv
; 85(4): 524-31, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24753036
10.
Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
Catheter Cardiovasc Interv
; 85(3): E76-82, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25339110
11.
Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Catheter Cardiovasc Interv
; 85(1): 74-81, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24585502
12.
Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.
Am Heart J
; 167(4): 445-51, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24655691
13.
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.
J Am Heart Assoc
; 7(3)2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29382666
14.
"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.
JACC Cardiovasc Interv
; 11(5): 448-459, 2018 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29454724
15.
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
JACC Cardiovasc Interv
; 11(5): 462-469, 2018 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519378
16.
Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population.
EuroIntervention
; 14(9): e1049-e1056, 2018 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29313817
17.
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
EuroIntervention
; 13(10): 1168-1176, 2017 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29151439
18.
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiol
; 2(3): 268-276, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28114618
19.
Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial.
EuroIntervention
; 12(17): 2128-2131, 2017 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27916746
20.
Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS.
J Cardiol
; 69(4): 660-665, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27476343